INFECTION AND IMMUNITY is a distinguished peer-reviewed journal published by the American Society for Microbiology, focusing on groundbreaking research in the fields of infection, immunology, microbiology, and parasitology. Established in 1971, this journal has built a robust legacy, converging years of scientific discovery with a vision towards 2024 and beyond. With an impressive Impact Factor, the journal holds significant rankings in various categories; its Q1 status in both Infectious Diseases and Parasitology underscores its high relevance and quality within the scientific community. Researchers and professionals alike will benefit from its content, as it promotes the latest advances in understanding immune responses and infectious agents, further legitimizing its place among the top quartiles of its respective fields. Access options are provided through traditional subscription models, ensuring a broad charitable dissemination of knowledge. As a pivotal resource for scholars and practitioners alike, INFECTION AND IMMUNITY stands at the forefront of microbiological and immunological research, fostering essential discourse that is crucial for advancing public health and scientific insight.

IMMUOLOGY LETTERS, published by Elsevier, is a distinguished journal in the field of immunology, focusing on the latest advancements and findings that significantly influence immunological research and clinical applications. Established in 1979, the journal has evolved to cater to a global readership, featuring high-quality peer-reviewed articles across a diverse spectrum of topics related to immunity and allergic responses. With an impressive Q2 category ranking in both Immunology and Allergy as of 2023, it holds a strong position within the scientific community, evidenced by its commendable Scopus rankings (Rank #71/233 in Medicine - Immunology and Allergy and Rank #85/236 in Immunology and Microbiology - Immunology). While primarily subscription-based, the journal aims to foster knowledge dissemination that encourages collaboration among researchers and practitioners alike, making significant contributions to the understanding of immune mechanisms. The journal is integral for educators, students, and professionals aiming to stay abreast of current trends and breakthroughs in the immune system's intricate functions.

TRENDS IN IMMUNOLOGY, published by CELL PRESS, stands as a premier source of insights and developments within the field of immunology. With an ISSN of 1471-4906 and E-ISSN of 1471-4981, this journal has established a strong reputation, evidenced by its prestigious status in Q1 quartiles for both Immunology and Allergy in 2023. It is ranked #13 out of 233 in the Scopus category of Medicine – Immunology and Allergy, and #16 out of 236 in Immunology and Microbiology, placing it within the top 94th and 93rd percentiles respectively. Since its inception in 1987, TRENDS IN IMMUNOLOGY has provided a critical platform for researchers, professionals, and students to access the latest advancements and integrative reviews in immunological research. The journal offers open access options, enhancing the accessibility of its high-impact content to a global audience. Researchers and practitioners rely on its pages not only for cutting-edge findings but also for comprehensive discussions that drive the future of immunology research.

Science Immunology, published by the American Association for the Advancement of Science, is a leading journal in the field of immunology, recognized for its significant impact and rigor in advancing our understanding of immune responses and complex diseases. With an impressive impact factor that places it in the Q1 category of both immunology and allergy, as well as miscellaneous medicine, this journal is ranked #7 and #8 in their respective Scopus categories, reflecting its high-quality research output. Since its inception in 2016, Science Immunology has been at the forefront of interdisciplinary immunological research, fostering crucial insights that link immunology with pressing health challenges. The journal is committed to providing open access to its content, ensuring that groundbreaking findings are accessible to a global audience of researchers, professionals, and students. Its anthology not only addresses fundamental immunological mechanisms but also enhances the dialogue on translational applications and therapeutic interventions, solidifying its position as an essential resource within the scientific community.

PARASITE IMMUNOLOGY, published by Wiley, is a leading journal in the field of immunology and parasitology, with an ISSN of 0141-9838 and E-ISSN of 1365-3024. Since its inception in 1979, it has played a pivotal role in advancing our understanding of host-parasite interactions, immunological responses to parasitic infections, and the mechanisms of immunological resistance. The journal is adeptly positioned within the academic community, currently holding a prestigious Q2 ranking in Parasitology and a Q3 ranking in Immunology for 2023, indicating its significant influence and relevance. Its comprehensive scope attracts a diverse readership, contributing to the discourse surrounding novel therapeutic approaches and emerging challenges in parasitic diseases. With a consistent convergence of research until 2024, PARASITE IMMUNOLOGY is an essential resource for researchers, professionals, and students seeking to deepen their knowledge and foster collaboration in these dynamic fields. Although it is not an open-access journal, the insights shared within its pages are invaluable for shaping future research trajectories.

HUMAN IMMUNOLOGY, published by Elsevier Science Inc, serves as a critical platform for disseminating research in the fields of immunology and allergy, as well as various aspects of miscellaneous medicine since its inception in 1980. With an ISSN of 0198-8859 and E-ISSN 1879-1166, this journal is pivotal for researchers and practitioners looking to advance their understanding of human immune responses and related conditions. The journal currently holds a respectable position within its field, as highlighted by its 2023 Scopus ranks—#114/233 in Immunology and Allergy and #132/236 in Immunology and Microbiology. Moreover, it maintains a Q2 quartile ranking in both Immunology and Allergy and miscellaneous Medicine, underscoring its influence and reach within the scientific community. Although it does not currently offer Open Access options, HUMAN IMMUNOLOGY remains dedicated to providing valuable insights and fostering academic discourse within its discipline, characterized by a rigorous peer-review process and a focus on innovative research trajectories.

IMMUNOBIOLOGY is a prestigious academic journal published by Elsevier GmbH that significantly contributes to the fields of hematology and immunology. With its ISSN 0171-2985 and E-ISSN 1878-3279, this journal has been disseminating impactful research since 1979, positioning itself at the forefront of immunological and hematological advances. The journal holds a commendable ranking of Q2 in Hematology and Q3 in both Immunology and Immunology and Allergy, indicating its relevance and influence within the scientific community, as reflected by its Scopus rankings. Although IMMUNOBIOLOGY operates under a subscription model, it remains dedicated to expanding knowledge across disciplines, fostering innovative research, and facilitating connections among researchers, professionals, and students. Situated in Munich, Germany, this journal is continually evolving and aims to remain an essential resource for the latest discoveries and insights in the realms of immunity and blood disorders, ultimately enhancing our understanding of complex biological systems.

CELLULAR IMMUNOLOGY is a prestigious journal published by Academic Press Inc. Elsevier Science, dedicated to advancing the field of immunology. Established in 1970 and converging ongoing research up to 2024, this journal has carved out a significant niche within the academic community, boasting a notable Q2 ranking in the Immunology category and holding a respectable 67th percentile ranking within Scopus for its contributions to the disciplines of Immunology and Microbiology. The journal serves as a vital platform for disseminating high-quality research, reviews, and methodologies that elucidate the intricacies of cellular immune responses, thereby benefiting researchers, professionals, and students alike. Although it does not offer open access, the journal's impact is evidenced by its comprehensive coverage of pioneering studies and ongoing developments in the immunological sciences, positioning it as an essential resource for those seeking to deepen their understanding and engage with the latest findings in cellular immunology.

JOURNAL OF EXPERIMENTAL MEDICINE, published by Rockefeller University Press, is a renowned peer-reviewed journal dedicated to advancing the field of experimental medicine since its inception in 1896. With an impressive impact factor and categorized in the Q1 quartile for Immunology, Immunology and Allergy, and Miscellaneous Medicine, this journal stands at the forefront of medical research and innovation. It provides a prestigious platform for scholars and practitioners to disseminate groundbreaking findings that drive the understanding of disease mechanisms and therapeutic strategies. While the journal is not open access, it maintains high visibility and engagement within the scientific community, fostering collaboration among researchers, professionals, and students alike. The journal's consistent ranking in the top percentiles of Scopus illustrates its significant impact and commitment to excellence in medical research.

Cancer Cell, published by Cell Press, represents a pinnacle of research in the fields of cancer research, cell biology, and oncology. With an impressive Impact Factor and ranking as Q1 in prestigious categories for both 2023 and previous years, this journal stands out as a vital resource for professionals and scholars dedicated to understanding the molecular underpinnings of cancer. Operating from Cambridge, MA, Cancer Cell has been an essential platform for innovative studies since its inception in 2002. Although it is not an Open Access journal, its rigorous peer-review process ensures that only the highest quality research is disseminated to the scientific community. Readers can expect to find a wealth of knowledge ranging from cutting-edge therapies to insights into tumor biology, thereby contributing significantly to the advancement of oncology. With rankings placing it among the top echelons of related fields—#2 in Cancer Research and #6 in Oncology—Cancer Cell is an indispensable reference for anyone committed to the fight against cancer.